Persisitent Local Cutaneous Atrophy Following Corticosteroid Injection for Tendinitis

Lund, Inger Marstrand; Donde, René; Knudsen, Erick A.

doi:10.1093/rheumatology/18.2.91

Cited by 24 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Necrotizing fasciitis after corticosteroid injection for trigger finger was presented as another severe complication [18]. Six studies described hypopigmentation of the skin [19-24], and two studies described atrophy of the skin [21,23]. Atrophy of the plantar fat pad was reported after injecting an interdigital neuroma, and another group reported perilymphatic atrophy [25,26].…”

Section: Resultsmentioning

confidence: 99%

Adverse effects of extra-articular corticosteroid injections: a systematic review

Brinks

Koes

Volkers

et al. 2010

BMC Musculoskelet Disord

189

122

View full text Add to dashboard Cite

BackgroundTo estimate the occurrence and type of adverse effects after application of an extra-articular (soft tissue) corticosteroid injection.MethodsA systematic review of the literature was made based on a PubMed and Embase search covering the period 1956 to January 2010. Case reports were included, as were prospective and retrospective studies that reported adverse events of corticosteroid injection. All clinical trials which used extra-articular corticosteroid injections were examined. We divided the reported adverse events into major (defined as those needing intervention or not disappearing) and minor ones (transient, not requiring intervention).ResultsThe search yielded 87 relevant studies:44 case reports, 37 prospective studies and 6 retrospective studies. The major adverse events included osteomyelitis and protothecosis; one fatal necrotizing fasciitis; cellulitis and ecchymosis; tendon ruptures; atrophy of the plantar fat was described after injecting a neuroma; and local skin effects appeared as atrophy, hypopigmentation or as skin defect. The minor adverse events effects ranged from skin rash to flushing and disturbed menstrual pattern. Increased pain or steroid flare after injection was reported in 19 studies. After extra-articular injection, the incidence of major adverse events ranged from 0-5.8% and that of minor adverse events from 0-81%. It was not feasible to pool the risk for adverse effects due to heterogeneity of study populations and difference in interventions and variance in reporting.ConclusionIn this literature review it was difficult to accurately quantify the incidence of adverse effects after extra-articular corticosteroid injection. The reported adverse events were relatively mild, although one fatal reaction was reported.

show abstract

Section: Resultsmentioning

confidence: 99%

Adverse effects of extra-articular corticosteroid injections: a systematic review

Brinks

Koes

Volkers

et al. 2010

BMC Musculoskelet Disord

189

122

View full text Add to dashboard Cite

show abstract

“…It generally begins within 2 to 3 months of injection and may resolve spontaneously within 1 to 2 years 3–6 . However, atrophy persisting beyond 5 years has been reported 7 . The extent and time course of cutaneous atrophy depend on the solubility and concentration of the CS preparation and the depth and anatomic location of injection 8 .…”

Section: Discussionmentioning

confidence: 99%

Treatment of Local, Persistent Cutaneous Atrophy Following Corticosteroid Injection with Normal Saline Infiltration

Shumaker

Rao

Goldman

2006

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…The diminishing vascularity of the Achilles tendon with advancing age [7] and steroid use [8] has been demonstrated. JORGENSEN et al [9] proposed that tendon rupture might be due to a vascular phenomenon leading to ischaemia.…”

Section: Discussionmentioning

confidence: 99%

Achilles tendon disease in lung transplant recipients: association with ciprofloxacin

Pn¹,

Ml²,

Pm³

et al. 2002

European Respiratory Journal

View full text Add to dashboard Cite

Achilles tendon disease in lung transplant recipients: association with ciprofloxacin. P.N. Chhajed, M.L. Plit, P.M. Hopkins, M.A. Malouf, A.R. Glanville. #ERS Journals Ltd 2002. ABSTRACT: Achilles tendonitis or rupture are uncommon complications following the use of fluoroquinolones, with a reported incidence in the general population of 0.4%. The aims of the current study were to determine the incidence of Achilles tendon disease (ATD) in lung transplant recipients (LTR) and to identify risk factors.Questionnaires were sent to 150 LTR of whom 101 responded (67%). Twenty-two LTR (21.8%) experienced ATD (tendonitis 16, rupture six). The mean age of LTR who developed ATD was 52.9 ¡ 6.1 yrs (range: 19-63.5 yrs).Only the use of ciprofloxacin was significantly associated with ATD (pv0.05). Age, sex, underlying disease necessitating transplantation, serum creatinine and cyclosporine levels were not associated with ATD. The association between ciprofloxacin and ATD was not dose related. Of the 72 LTR who had received ciprofloxacin, 20 (28%) developed ATD (tendonitis 15, rupture five). In patients receiving ciprofloxacin, there was no association between the mean cumulative dose of prednisolone and ATD. Tendon rupture occurred with a lower ciprofloxacin dosage than tendonitis and the mean recovery duration was significantly longer.To conclude, lung transplant recipients receiving ciprofloxacin are at significant risk of developing Achilles tendon disease. The association between ciprofloxacin and Achilles tendon disease appears to be idiosyncratic rather than dose-related.

show abstract

Persisitent Local Cutaneous Atrophy Following Corticosteroid Injection for Tendinitis

Cited by 24 publications

References 0 publications

Adverse effects of extra-articular corticosteroid injections: a systematic review

Adverse effects of extra-articular corticosteroid injections: a systematic review

Treatment of Local, Persistent Cutaneous Atrophy Following Corticosteroid Injection with Normal Saline Infiltration

Achilles tendon disease in lung transplant recipients: association with ciprofloxacin

Contact Info

Product

Resources

About